Migaczewski Marcin, Zub-Pokrowiecka Anna, Budzyński Piotr, Matłok Maciej, Budzyński Andrzej
2 Department of General Surgery, Medical College Jagiellonian University, Krakow, Poland.
Wideochir Inne Tech Maloinwazyjne. 2012 Jun;7(2):105-10. doi: 10.5114/wiitm.2011.27151. Epub 2012 Mar 27.
Surgical site infection (SSI) appear to be more frequent in splenectomized patients than might be expected and its incidence can be explained neither by the extent of surgery nor by the risk of bacterial contamination of the operating field.
Evaluation the local antibiotic prophylaxis using a gentamicin surgical implant in order to reduce SSI, particularly subphrenic abscesses.
WE CONDUCTED A PROSPECTIVE, RANDOMIZED STUDY OF TWO GROUPS OF PATIENTS UNDERGOING LAPAROSCOPIC SPLENECTOMY WHO WERE CONSIDERED AT HIGH RISK OF INFECTIVE COMPLICATIONS: patients with idiopathic thrombocytopenic purpura (ITP) pre-treated chronically with systemic steroids and patients with non-Hodgkin lymphoma (NHL). Out of 98 laparoscopic splenectomies performed during the study period, 40 patients with ITP and 20 with NHL met the inclusion criteria and were enrolled in the study. In 20 randomly selected patients with ITP and 10 with NHL, a gentamicin-collagen implant was left in the splenic bed.
Infective complications occurred in 4 (6.67%) among 60 patients from the entire study group; 2 in patients with ITP and a gentamicin implant who developed fever of unknown cause which resolved after systemic antibiotics, and 2 in patients with NHL and gentamicin prophylaxis who developed a subphrenic abscess. In all patients operated on without a gentamicin implant, the postoperative course was uncomplicated.
Gentamicin surgical implants not only fail to reduce the risk of subphrenic abscesses in splenectomized patients, but may contribute to the increase in its incidence, which puts into question the possible benefits of this form of prophylaxis.
脾切除患者手术部位感染(SSI)的发生率似乎比预期更高,其发生率既不能用手术范围来解释,也不能用手术区域细菌污染的风险来解释。
评估使用庆大霉素外科植入物进行局部抗生素预防以减少SSI,特别是膈下脓肿。
我们对两组接受腹腔镜脾切除术且被认为有感染并发症高风险的患者进行了一项前瞻性随机研究:长期接受全身类固醇预处理的特发性血小板减少性紫癜(ITP)患者和非霍奇金淋巴瘤(NHL)患者。在研究期间进行的98例腹腔镜脾切除术中,40例ITP患者和20例NHL患者符合纳入标准并被纳入研究。在20例随机选择的ITP患者和10例NHL患者中,将庆大霉素 - 胶原植入物留在脾床。
整个研究组的60例患者中有4例(6.67%)发生感染并发症;2例为植入庆大霉素的ITP患者,出现不明原因发热,经全身抗生素治疗后缓解,2例为接受庆大霉素预防的NHL患者,发生膈下脓肿。在所有未植入庆大霉素的手术患者中,术后过程均无并发症。
庆大霉素外科植入物不仅未能降低脾切除患者膈下脓肿的风险,反而可能导致其发生率增加,这使这种预防形式的潜在益处受到质疑。